mRNA |
pifithrin-mu |
CTRPv2 |
pan-cancer |
AAC |
-0.032 |
0.4 |
mRNA |
Crizotinib |
GDSC1000 |
pan-cancer |
AAC |
0.048 |
0.4 |
mRNA |
GDC-0941 |
GDSC1000 |
pan-cancer |
AAC |
-0.029 |
0.4 |
mRNA |
IPR-456 |
CTRPv2 |
pan-cancer |
AAC |
0.034 |
0.4 |
mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.031 |
0.4 |
mRNA |
Axitinib |
GDSC1000 |
pan-cancer |
AAC |
-0.031 |
0.4 |
mRNA |
RAF265 |
CCLE |
pan-cancer |
AAC |
-0.043 |
0.4 |
mRNA |
GSK4112 |
CTRPv2 |
pan-cancer |
AAC |
-0.033 |
0.4 |
mRNA |
tretinoin:carboplatin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.031 |
0.4 |
mRNA |
ML050 |
CTRPv2 |
pan-cancer |
AAC |
0.033 |
0.4 |